Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Hepatitis B or hepatitis C coinfection in HIV-infected pregnant women in Europe
HIV Medicine, Volume 9, No. 7, Year 2008
Notification
URL copied to clipboard!
Description
Objectives: The aim of the study was to investigate the prevalence of and risk factors for hepatitis C or B virus (HCV or HBV) coinfection among HIV-infected pregnant women, and to investigate their immunological and virological characteristics and antiretroviral therapy use. Methods: Information on HBV surface antigen (HBsAg) positivity and HCV antibody (anti-HCV) was collected retrospectively from the antenatal records of HIV-infected women enrolled in the European Collaborative Study and linked to prospectively collected data. Results: Of 1050 women, 4.9% [95% confidence interval (CI) 3.6-6.3] were HBsAg positive and 12.3% (95% CI 10.4 - 14.4) had anti-HCV antibody. Women with an injecting drug use(r) (IDU) history had the highest HCV-seropositivity prevalence (28%; 95% CI 22.8 - 35.7). Risk factors for HCV seropositivity included IDU history [adjusted odds ratio (AOR) 2.92; 95% CI 1.86-4.58], age (for ≥ 35 years vs. <25 years, AOR 3.45; 95% CI 1.66 - 7.20) and HBsAg carriage (AOR 5.80; 95% CI 2.78 - 12.1). HBsAg positivity was associated with African origin (AOR 2.74; 95% CI 1.20 - 6.26) and HCV seropositivity (AOR 6.44; 95% CI 3.08 - 13.5). Highly active antiretroviral therapy (HAART) use was less likely in HIV/HCV-seropositive than in HIV-monoinfected women (AOR 0.34; 95% CI 0.20-0.58). HCV seropositivity was associated with a higher adjusted HIV RNA level (+ 0.28 log10 HIV-1 RNA copies/mL vs. HIV-monoinfected women; P = 0.03). HIV/HCV-seropositive women were twice as likely to have detectable HIV in the third trimester/delivery as HIV-monoinfected women (AOR 1.95; P = 0.049). Conclusions: Although HCV serostatus impacted on HAART use, the association between HCV seropositivity and uncontrolled HIV viraemia in late pregnancy was independent of HAART. © 2008 British HIV Association.
Authors & Co-Authors
Landes, Megan
Canada, Toronto
University of Toronto
Newell, Marie Louise
United Kingdom, London
Ucl Great Ormond Street Institute of Child Health
South Africa, Durban
University of Kwazulu-natal
Barlow, Patricia
Belgium, Brussels
Centre Hospitalier Universitaire Saint Pierre, Brussels
Fiore, Simona
Italy, Milan
Ospedale Luigi Sacco - Polo Universitario
Malyuta, Ruslan
Ukraine, Odessa
Perinatal Prevention of Aids Initiative, Odessa
Martinelli, Pasquale
Italy, Naples
Università Degli Studi Di Napoli Federico Ii
Posokhova, Svetlana
Ukraine, Odessa
Odessa Regional Radio-broadcasting Center
Savasi, Valeria Maria
Italy, Milan
Ospedale Luigi Sacco - Polo Universitario
Semenenko, Igor
Ukraine, Odessa
Perinatal Prevention of Aids Initiative, Odessa
Stelmah, Andrej
Ukraine, Simferopol
Crimean Republican Aids Center
Tibaldi, Cecilia
Italy, Turin
Azienda Ospedaliera - Universitaria Città Della Salute e Della Scienza Di Torino
Thorne, Claire N.
United Kingdom, London
Ucl Great Ormond Street Institute of Child Health
Statistics
Citations: 83
Authors: 12
Affiliations: 10
Identifiers
Doi:
10.1111/j.1468-1293.2008.00599.x
ISSN:
14642662
e-ISSN:
14681293
Research Areas
Infectious Diseases
Maternal And Child Health
Sexual And Reproductive Health
Study Design
Cross Sectional Study
Case-Control Study
Participants Gender
Female